An oral preparation for treating cell proliferation diseases. The oral preparation comprises hydroxylpropoxyl-β-cyclodextrin and an active component. The active component is KX2-361 or a medicinal salt thereof, and KX2-361 is represented by formula 1. By mixing hydroxylpropoxyl-ydcyclodextrin with KX2-361 or the medicinal salt thereof, an inclusion complex is formed, the solubility of the poorly-soluble drug KX2-361 is greatly improved, and accordingly the drug is prepared into an oral preparation. The oral preparation has good stability, high safety, good absorbability, high bioavailability and economical cost.
A61K 9/19 - Préparations médicinales caractérisées par un aspect particulier à l'état particulaire, p. ex. poudres lyophilisées
A61K 47/69 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament le conjugué étant caractérisé par sa forme physique ou sa forme galénique, p. ex. émulsion, particule, complexe d’inclusion, stent ou kit
2.
Drug inclusion complex, preparation thereof, and preparation method thereof
A pharmaceutical composition comprises an active component KX2-361 represented by formula 1 or a medicinal salt thereof and hydroxylpropoxyl-β-cyclodextrin. An inclusion compound is formed by KX2-361 or the medicinal salt thereof and hydroxylpropoxyl-β-cyclodextrin, and the solubility of the poorly-soluble drug KX2-361 is improved. The pharmaceutical composition can be prepared into an intravenous preparation and an oral preparation.
A61K 47/69 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament le conjugué étant caractérisé par sa forme physique ou sa forme galénique, p. ex. émulsion, particule, complexe d’inclusion, stent ou kit
A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
A pharmaceutical composition comprises an active component KX2-361 represented by formula 1 or a medicinal salt thereof and hydroxylpropoxyl-β-cyclodextrin. An inclusion compound is formed by KX2-361 or the medicinal salt thereof and hydroxylpropoxyl-β-cyclodextrin, and the solubility of the poorly-soluble drug KX2-361 is improved. The pharmaceutical composition can be prepared into an intravenous preparation and an oral preparation.
An oral preparation for treating cell proliferation diseases. The oral preparation comprises hydroxylpropoxyl-β-cyclodextrin and an active component. The active component is KX2-361 or a medicinal salt thereof, and KX2-361 is represented by formula 1. By mixing hydroxylpropoxyl-β-cyclodextrin with KX2-361 or the medicinal salt thereof, an inclusion compound is formed, the solubility of the poorly-soluble drug KX2-361 is greatly improved, and accordingly the drug is prepared into an oral preparation. The oral preparation has good stability, high safety, good absorbability, high bioavailability and economical cost.
GUANGDONG HUAZHOU TRADITIONAL CHINESE MEDICINE FACTORY PHARMACEUTICAL CO., LTD. (Chine)
GUANGDONG JOCHI BIOTECHNOLGY CO., LTD. (Chine)
Inventeur(s)
Wang, Yonghui
Zeng, Yi
Kang, Zhiying
Zeng, Lun
Fu, Fangfei
Abrégé
A liquid packaging bag (10), comprising a bag body (100), a bag neck (200) and a grasping member (300). The bag body has a bottom portion and a top portion, and an accommodation cavity (110) for accommodating a liquid. The bag neck is connected to the top portion of the bag body. The bag neck is provided with a tube (210) for providing a liquid flow, the tube communicating with the accommodation cavity. The bag neck has a notch formed for tearing open the bag neck and opening an easy-tear hole of the tube. The grasping member is connected to the bag body. The liquid packaging bag is easily torn open and the liquid in the bag does not readily spill out.
GUANGDONG HUAZHOU TRADITIONAL CHINESE MEDICINE FACTORY PHARMACEUTICAL CO., LTD. (Chine)
GUANGDONG JOCHI BIOTECHNOLGY CO., LTD. (Chine)
Inventeur(s)
Wang, Yonghui
Zeng, Yi
Kang, Zhiying
Zeng, Lun
Fu, Fangfei
Abrégé
A liquid packaging bottle, comprising a bottle body, a sucking tube, a first twist opening member and second twist opening member. The bottle body has an accommodation cavity for accommodating liquid. A first opening and second opening are provided on the bottle body. A dimension of the first opening is larger than that of the second opening. The first opening and second opening each communicate with the accommodation cavity. The sucking tube is disposed within the accommodation cavity and is connected to the accommodation cavity inner wall. One end of the sucking tube communicates with the first opening, and another end is disposed at the bottom of the accommodation cavity. The sucking tube is adhered to the accommodation cavity inner wall. The first twist opening member is connected to the bottle body and seals the first opening. When the first twist opening member separates from the bottle body, the first opening opens. The second twist opening member is connected to bottle body, and seals the second opening. When the second twist opening member separates from the bottle body, the second opening opens. The liquid packaging bottle thus maintains the seal of the liquid inside the bottle, and prevents external contaminants from entering the bottle.
Provided are a T cell receptor (TCR) and a molecule thereof fused with a therapeutic agent. The binding affinity of the TCR with respect to SLLMWITQC-HLA A2 complex is at least twice of that of a wild-type TCR. The TCR either can be used independently or can be used jointly with the therapeutic agent.
C12N 15/12 - Gènes codant pour des protéines animales
C12N 15/63 - Introduction de matériel génétique étranger utilisant des vecteursVecteurs Utilisation d'hôtes pour ceux-ciRégulation de l'expression
C12N 5/10 - Cellules modifiées par l'introduction de matériel génétique étranger, p. ex. cellules transformées par des virus
A61K 38/17 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains
A61K 47/48 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p.ex. supports, additifs inertes l'ingrédient non actif étant chimiquement lié à l'ingrédient actif, p.ex. conjugués polymère-médicament
Provided is a high-stability T cell receptor (TCR). The TCR comprises (i) the whole or a part of TCRα chain except a transmembrane domain thereof, and (ii) the whole or a part of TCRβ chain except a transmembrane domain thereof, both the (i) and the (ii) comprising a functional variable domain and at least a part of a constant domain of a TCR chain. An artificial interchain disulfide bond links the constant domains of the TCRα and β chains, and a Tm value of the T cell receptor is greater than or equal to 45ºC.
C12N 15/12 - Gènes codant pour des protéines animales
C12N 15/63 - Introduction de matériel génétique étranger utilisant des vecteursVecteurs Utilisation d'hôtes pour ceux-ciRégulation de l'expression
C12N 1/21 - BactériesLeurs milieux de culture modifiés par l'introduction de matériel génétique étranger
A61K 38/17 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains
Provided is a T cell receptor(TCR), combining with KLVALGINAV-HLA-A 2 compound and comprising a TCR α variable domain and/or TCR β variable domain. Also provided is a fusion of a TCR and a therapeutic agent. The TCR can be used separately, and in combination with the therapeutic agent, for target presenting of HCV infection cells of a KLVALGINAV-HLA-A 2 compound.
C12N 15/12 - Gènes codant pour des protéines animales
C12N 15/63 - Introduction de matériel génétique étranger utilisant des vecteursVecteurs Utilisation d'hôtes pour ceux-ciRégulation de l'expression
C12N 5/10 - Cellules modifiées par l'introduction de matériel génétique étranger, p. ex. cellules transformées par des virus
A61K 38/17 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains
The present invention provides a high-stability T-cell receptor, a hydrophobic core region of said T-cell receptor having undergone a mutation, leading to the increased stability thereof. The present invention additionally provides a preparation method and an application of the T-cell receptor.
C12N 15/12 - Gènes codant pour des protéines animales
C12N 15/63 - Introduction de matériel génétique étranger utilisant des vecteursVecteurs Utilisation d'hôtes pour ceux-ciRégulation de l'expression
C12N 15/10 - Procédés pour l'isolement, la préparation ou la purification d'ADN ou d'ARN
A61K 47/48 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p.ex. supports, additifs inertes l'ingrédient non actif étant chimiquement lié à l'ingrédient actif, p.ex. conjugués polymère-médicament
A61K 38/17 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains
brevets
